Compounds are provided that act as potent antagonists of the CCR1 receptor,and have in vivo anti-inflammatoryactivity. The compounds are 4-amino-3-imidazoyl-pyrazolo[3,4-d]pyrimidinederivatives and are useful in pharmaceutical compositions,methods for the treatment of CCR1-mediated disease, and as controls in assaysfor the identification of competitive CCR1antagonists.